Lilly to acquire SGX Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Lillyis to acquire SGX Pharmaceuticals in an all-cash deal for around $64 million, or $3 per outstanding share of the US-based biotechnology company's stock.